The ASC industry continued to expand in 2024, with major players pursuing aggressive growth strategies through acquisitions, joint ventures and de novo developments.
Category: Becker’s ASC Review
UCSF Health opening $60M ASC
UCSF Health has opened a $60 million, four-story outpatient center in Burlingame, Calif., according to a March 3 report from the San Francisco Business Times.
Physician sues former practice over $20M PE deal
An Orchard Park, N.Y.-based radiologist is suing his former practice, claiming he was shortchanged when it sold assets to private equity firm Rezolut for $20 million in 2023, Buffalo Business First reported Feb. 27.
3 hospitals, health systems investing in ASCs
Here are three hospitals and health systems investing in ASCs, as reported by Becker’s:
NYC Health + Hospitals taps new medical director of ambulatory care
Michelle Soto, MD, has been appointed as medical director of ambulator care at NYC Health + Hospitals/North Central Bronx in New York City.
Why 'culture' is key for ASC-hospital dynamics
ASC hospital dynamics have been evolving over the last several years as hospitals look increasingly to ASCs for their cost-savings potential and benefits to patients.
Ascension's sale of 8 hospitals, 2 ASCs completed
Ontario, Calif.-based Prime Healthcare completed its acquisition of eight Ascension hospitals and two ASCs in Illinois.
FTC forms new antitrust task force
In his first public appearance at the end of February, FTC Chairman Andrew Ferguson announced the agency’s plan to address corporations violating antitrust and consumer protection laws, breaking with traditional Republican priorities at the organizatio…
Guardant accuses Natera of trade secret theft amid 'jealousy' over CRC blood test
Guardant Health has filed a lawsuit against its competitor, Natera, alleging the misappropriation of trade secrets related to cancer-detection blood tests, according to court documents.
Surgery Partners revenue hits $3.1B in 2024
Brentwood, Tenn.-based Surgery Partners’ deployed nearly $400 million on acquisitions and opened eight de novo facilities in 2024, according to the company’s financial report released March 3.
